Immunotherapy for hormone receptor-positive HER2-negative breast cancer

被引：0
|
作者：
Cardoso, Fatima [1 ]
Hirshfield, Kim M. [2 ]
Kraynyak, Kimberly A. [2 ]
Tryfonidis, Konstantinos [2 ]
Bardia, Aditya [3 ]
机构：
[1] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
[2] Merck & Co Inc, Rahway, NJ USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA USA
来源：
NPJ BREAST CANCER | 2024年 / 10卷 / 01期
关键词：
PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT ENDOCRINE THERAPY; OPEN-LABEL; HIGH-RISK; NEOADJUVANT CHEMOTHERAPY; LOCALLY RECURRENT; NIVOLUMAB NIVO; TRIAL; PALBOCICLIB;
D O I：
10.1038/s41523-024-00704-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.
引用
收藏
页数：15
相关论文
共 50 条
  • [31] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
    Ma, S. J.
    Oladeru, O. T.
    Sood, A. J.
    Mikucki, M.
    Farrugia, M. K.
    Singh, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
  • [32] A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer
    Harbeck, Nadia
    Burstein, Harold J.
    Hurvitz, Sara A.
    Johnston, Stephen
    Vidal, Gregory A.
    CANCER, 2022, 128 : 2209 - 2223
  • [33] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [34] Effectiveness of platinum-based chemotherapy for hormone receptor-positive HER2-negative metastatic breast cancer
    Uratani, Lucas Fernando
    Bermejo, Francesco Sansone
    Hashizume, Pedro HenriqueShimiti
    Bonadio, Renata Colombo
    Testa, Laura
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2-negative breast cancer
    Kearney, Matthew R.
    McGuinness, Julia E.
    Kalinsky, Kevin
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 1 - 13
  • [36] Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
    Torrisi, Rosalba
    Marrazzo, Emilia
    Agostinetto, Elisa
    De Sanctis, Rita
    Losurdo, Agnese
    Masci, Giovanna
    Tinterri, Corrado
    Santoro, Armando
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [37] Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Joo, Eun Hye
    Kim, Sangmin
    Park, Donghyun
    Lee, Taeseob
    Park, Woong-Yang
    Han, Kyung Yeon
    Lee, Jeong Eon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [38] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [39] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
    Schwartzberg, Lee S.
    Kiedrowski, Lesli A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [40] Protein-protein interaction of HER2 predicts the prognosis of hormone receptor-positive HER2-negative breast cancer
    Choi, Hee Jun
    Lee, Hong Won
    Kim, Sangmin
    Yoon, Tae-Young
    Kim, Hyunwoo
    Lee, Seul
    Nam, Seok Jin
    Kim, Seok Won
    Cho, Sooyoun
    Park, Yeon Hee
    Lee, Jeong Eon
    CANCER RESEARCH, 2020, 80 (04)
12345